Literature DB >> 14970040

Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke.

Adnan I Qureshi1, Amir M Siddiqui, Stanley H Kim, Ricardo A Hanel, Andrew R Xavier, Jawad F Kirmani, M Fareed K Suri, Alan S Boulos, L Nelson Hopkins.   

Abstract

BACKGROUND AND
PURPOSE: Early reocclusion of recanalized arteries has been observed after thrombolysis for acute coronary occlusion and has been attributed to platelet activation after exposure to thrombolytic agents. We conducted a retrospective study to determine the rate of reocclusion during intra-arterial thrombolysis for acute ischemic stroke and the effect of reocclusion on functional outcome.
METHODS: Patients treated for acute ischemic stroke at our center between September 2000 and May 2002 received a maximum total dose of 4 U of reteplase intra-arterially in 1-U increments via superselective catheterization. Pharmacologic thrombolysis was supplemented by mechanical thrombolysis with balloon angioplasty or snare manipulation at the occlusion site. Angiography was performed after each unit of reteplase or mechanical maneuver, and the images were interpreted by a blinded reviewer. Reocclusion was defined as partial or complete initial recanalization with occlusion recurring at the same site as documented by angiography during the endovascular treatment. Reocclusions were treated by further pharmacologic and/or mechanical thrombolysis according to the discretion of the treating physician. Clinical evaluations were performed before and 24 hr, 7 to 10 days, and 1 to 3 months after treatment.
RESULTS: Forty-six consecutive patients underwent intra-arterial thrombolysis. Reocclusion was observed in eight (17%). Among these patients, initial sites of occlusion were in the following arteries: intracranial internal carotid artery (n = 2), M1 segment of the middle cerebral artery (n = 3), M1 and M2 segments of the middle cerebral artery (n = 2), and basilar artery (n = 1). The mean initial National Institutes of Health Scale score for these eight patients was 23.3 +/- 6.2; mean time from symptom onset to treatment was 4.4 +/- 1.2 hr. The reocclusions were treated by using additional doses of reteplase alone (n = 1), reteplase with snare maneuver and/or angioplasty (n = 5), reteplase with angioplasty or snare and then stent placement (n = 1), and angioplasty with stent placement (n = 1). The reocclusions resolved in six of eight patients after further treatment. Six patients died and two survived but were severely disabled at 1 month (modified Rankin Scale scores of 4 and 5, respectively). Independent functional outcome scores (modified Rankin Scale scores of 0-2) were significantly lower among patients with angiographically shown reocclusion than in those without (0 of 8 versus 17 of 38, P =.02).
CONCLUSION: Reocclusion occurs relatively frequently during intra-arterial thrombolysis for ischemic stroke and seems to be associated with poor clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14970040      PMCID: PMC7974601     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

Review 1.  Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition.

Authors:  R M Califf
Journal:  Am Heart J       Date:  2000-02       Impact factor: 4.749

2.  Assessment of scales of disability and handicap for stroke patients.

Authors:  C D Wolfe; N A Taub; E J Woodrow; P G Burney
Journal:  Stroke       Date:  1991-10       Impact factor: 7.914

Review 3.  Augmentation of thrombolysis with antiplatelet drugs.

Authors:  B S Coller
Journal:  Coron Artery Dis       Date:  1995-12       Impact factor: 1.439

4.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

5.  Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.

Authors:  J C Grotta; K M Welch; S C Fagan; M Lu; M R Frankel; T Brott; S R Levine; P D Lyden
Journal:  Stroke       Date:  2001-03       Impact factor: 7.914

6.  Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.

Authors: 
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

7.  Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.

Authors:  Y Zhu; P Carmeliet; W P Fay
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

8.  Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study.

Authors:  Adnan I Qureshi; Amir M Siddiqui; M Fareed K Suri; Stanley H Kim; Zulfiqar Ali; Abutaher M Yahia; Demetrius K Lopes; Alan S Boulos; Andrew J Ringer; Mustafa Saad; Lee R Guterman; L Nelson Hopkins
Journal:  Neurosurgery       Date:  2002-11       Impact factor: 4.654

9.  Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator.

Authors:  Andrei V Alexandrov; James C Grotta
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

10.  New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke.

Authors:  Adnan I Qureshi
Journal:  Neurosurgery       Date:  2002-06       Impact factor: 4.654

View more
  32 in total

1.  Leptomeningeal collaterals in acute ischemic stroke.

Authors:  Nauman Tariq; Rakesh Khatri
Journal:  J Vasc Interv Neurol       Date:  2008-10

Review 2.  [Diagnosis and therapy of basilar artery occlusion].

Authors:  T Pfefferkorn; T E Mayer; G Schulte-Altedorneburg; H Brückmann; G F Hamann; M Dichgans
Journal:  Nervenarzt       Date:  2006-04       Impact factor: 1.214

Review 3.  Mechanical interventions to treat acute stroke.

Authors:  David Fussell; H Christian Schumacher; Philip M Meyers; Randall T Higashida
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

Review 4.  TIMI, TIBI, TICI: I came, I saw, I got confused.

Authors:  Thomas Tomsick
Journal:  AJNR Am J Neuroradiol       Date:  2007-02       Impact factor: 3.825

5.  Balloon-expandable stent placement in patients with immediate reocclusion after initial successful thrombolysis of acute middle cerebral arterial obstruction.

Authors:  H K Lee; H S Kwak; G H Chung; S B Hwang
Journal:  Interv Neuroradiol       Date:  2012-03-16       Impact factor: 1.610

6.  [Interventional endovascular therapy (stenting) for residual stenosis after lysis of the basilar artery].

Authors:  S Boy; K Isenhardt; K Gardill; B Kapp; R Schneider; J Berkefeld
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

7.  Subacute recanalization and reocclusion in patients with acute ischemic stroke following endovascular treatment.

Authors:  Adnan I Qureshi; Haitham M Hussein; Mohamed Abdelmoula; Alexandros L Georgiadis; Nazli Janjua
Journal:  Neurocrit Care       Date:  2008-12-03       Impact factor: 3.210

8.  Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study.

Authors:  H M Hussein; A L Georgiadis; G Vazquez; J T Miley; M Z Memon; Y M Mohammad; G A Christoforidis; N Tariq; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

9.  Self-expanding stents for recanalization of acute cerebrovascular occlusions.

Authors:  E I Levy; R Mehta; R Gupta; R A Hanel; A J Chamczuk; D Fiorella; H H Woo; F C Albuquerque; T G Jovin; M B Horowitz; L N Hopkins
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

10.  Impact of arterial reocclusion and distal fragmentation during thrombolysis among patients with acute ischemic stroke.

Authors:  N Janjua; A Alkawi; M F K Suri; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-16       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.